发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event. 特异性人类白细胞抗原等位基因与甲状腺免疫相关不良事件发生之间的关系。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2353539
Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji
{"title":"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.","authors":"Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji","doi":"10.1080/1750743X.2024.2353539","DOIUrl":"10.1080/1750743X.2024.2353539","url":null,"abstract":"<p><p><b>Aim:</b> Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.<b>Materials & methods:</b> In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.<b>Results:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [<i>p</i> = 0.004], 80.0 vs 45.2% [<i>p</i> = 0.020] and 55.0 vs 25.8% [<i>p</i> = 0.044], respectively).<b>Conclusion:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> appear to be associated with thyroid irAE.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"723-732"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy. 与免疫疗法有关的副肿瘤性皮肌炎和史蒂文斯-约翰逊综合征。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2362107
Katerina Kampoli, Ioannis Tsamis, Dimitrios Sgouros, Pelagia Katsimbri, Anna Koumarianou
{"title":"Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy.","authors":"Katerina Kampoli, Ioannis Tsamis, Dimitrios Sgouros, Pelagia Katsimbri, Anna Koumarianou","doi":"10.1080/1750743X.2024.2362107","DOIUrl":"10.1080/1750743X.2024.2362107","url":null,"abstract":"<p><p>Paraneoplastic syndromes such as dermatomyositis, often emerge as the initial clinical manifestation across various cancer types and are characterized by the development of B-cell responses targeting cancer-cell antigens that cross-react with normal skin and muscle cells. While these syndromes may alleviate following antineoplastic intervention, their response to immunotherapy remains elusive due to the exclusion of patients with autoimmune phenomena from clinical trials. In this report, we present the case of a female patient with advanced urothelial cancer presenting with dermatomyositis, who subsequently underwent treatment with anti-PD1 immunotherapy and experienced the onset of Stevens-Johnson syndrome. We discuss these two autoimmune entities and provide a comprehensive review of the existing literature to elucidate similar associations.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"709-714"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report. 双检查点抑制剂治疗后的恶性免疫相关性结肠炎：病例报告。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/1750743X.2024.2386234
Robert Lukin, Aaron Ciner
{"title":"Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report.","authors":"Robert Lukin, Aaron Ciner","doi":"10.1080/1750743X.2024.2386234","DOIUrl":"10.1080/1750743X.2024.2386234","url":null,"abstract":"<p><p><b>Aim:</b> Immune-related (IR) colitis is a potentially life-threatening complication of checkpoint inhibitors. Its presentation often includes diarrhea, abdominal pain and rectal bleeding and the median time to onset is 6-10 weeks post initiation of immunotherapy.<b>Case study:</b> We report an unusual case of fulminant IR-colitis beginning 3 days after the first dose of dual checkpoint blockade. IR-colitis was refractory to high-dose corticosteroids and was further complicated by sigmoid diverticulum perforation.<b>Conclusion:</b> Early-onset IR-colitis can occur, particularly in the context of combined anti-PD1 and anti-CTLA4 blockade, and clinicians should maintain a high-index of suspicion even when timing of symptom onset is atypical. Further research is needed to elucidate risk factors for early-onset IR-colitis.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"943-948"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bimekizumab for the treatment of hidradenitis suppurativa. 治疗化脓性扁桃体炎的比美单抗。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-19 DOI: 10.1080/1750743X.2024.2401308
Rayad B Shams, Christopher J Sayed
{"title":"Bimekizumab for the treatment of hidradenitis suppurativa.","authors":"Rayad B Shams, Christopher J Sayed","doi":"10.1080/1750743X.2024.2401308","DOIUrl":"10.1080/1750743X.2024.2401308","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a painful, inflammatory dermatosis involving recurrent abscesses, nodules and tunnels in intertriginous regions. Biologics and other immunomodulators have significantly expanded the treatment options available for HS. Bimekizumab is a monoclonal antibody targeting both interleukin-17A and interleukin-17F, key mediators of inflammation, that is already approved for psoriasis, psoriatic arthritis and axial spondylarthritis. It is currently pending FDA review for HS treatment but has already received marketing authorization for this indication in Europe. This review aims to explore drug-specific characteristics of bimekizumab including its mechanism of action, pharmacokinetics and pharmacodynamics and the current state of the literature regarding its use in HS such as safety, efficacy and dosing, while highlighting its implications in clinical practice. Recent Phase II and III trial data demonstrating positive efficacy and safety profiles in the treatment of HS will also be detailed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1005-1013"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma. 免疫相关不良事件对头颈部鳞状细胞癌患者生存期的影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-10-11 DOI: 10.1080/1750743X.2024.2409617
Omar Elghawy, Adam Barsouk, Reema Patel, Lauren Reed-Guy, John S Wang, Jessica Xu, Austin Yang, Jonathan Sussman, Varinder Kaur
{"title":"Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma.","authors":"Omar Elghawy, Adam Barsouk, Reema Patel, Lauren Reed-Guy, John S Wang, Jessica Xu, Austin Yang, Jonathan Sussman, Varinder Kaur","doi":"10.1080/1750743X.2024.2409617","DOIUrl":"10.1080/1750743X.2024.2409617","url":null,"abstract":"<p><p><b>Aim:</b> Immune-checkpoint inhibitors (ICIs) have revolutionized treatment of metastatic head and neck squamous cell carcinomas (HNSCCs). Our goal was to assess for an association between immune-related adverse events (irAEs) and clinical outcomes for patients on ICIs.<b>Methods:</b> We analyzed a cohort of 110 HNSCC patients who received ICI therapy at the University of Virginia.<b>Results:</b> On review, 48% of our patients experienced an irAE with the most common events being hypothyroidism (30%), dermatitis (14%) and hepatitis (11%). Women were more likely to experience irAEs. Treatment interruption/discontinuation occurred in 43% patients with irAEs. Development of irAEs was associated with superior objective response rate (68 vs. 39%, <i>p</i> = 0.009), with a greater rate of CR (17 vs. 5%) and PR (32 vs. 16%). Twelve patients underwent ICI re-treatment following irAE, with 17% attaining a complete disease response, 25% attaining a partial response, 33% achieving stable disease and 25% experiencing disease progression with ICI resumption.<b>Conclusion:</b> Development of irAE was associated with superior objective response rate, with a greater rate of CR and PR. ICI re-treatment following irAE was feasible in a significant proportion of patients and can be attempted in carefully selected patients, given the dearth of second-line therapies for these patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1069-1078"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. 用贝那利珠单抗治疗中重度特应性皮炎：HILLIER 研究结果简明摘要。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-05-02 DOI: 10.2217/imt-2023-0319
Emma Guttman-Yassky, Lila Bahadori, Laura Brooks, Ken L Clark, Hanna Grindebacke, Calvin N Ho, Rohit Katial, Tuyet-Hang Pham, Claire Walton, Catherine J Datto
{"title":"Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary.","authors":"Emma Guttman-Yassky, Lila Bahadori, Laura Brooks, Ken L Clark, Hanna Grindebacke, Calvin N Ho, Rohit Katial, Tuyet-Hang Pham, Claire Walton, Catherine J Datto","doi":"10.2217/imt-2023-0319","DOIUrl":"10.2217/imt-2023-0319","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"641-648"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11407287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand? CAR-T细胞治疗H3K27改变的弥漫中线胶质瘤：我们的现状如何？
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI: 10.1080/1750743X.2024.2373043
Erica A Power, Elena Millesi, Julian S Rechberger, David J Daniels
{"title":"CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?","authors":"Erica A Power, Elena Millesi, Julian S Rechberger, David J Daniels","doi":"10.1080/1750743X.2024.2373043","DOIUrl":"10.1080/1750743X.2024.2373043","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"775-778"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors. 低钠值对接受免疫检查点抑制剂的癌症患者生存结果的影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI: 10.1080/1750743X.2024.2370231
Beliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, Eda Eylemer Mocan, Elif Berna Köksoy, Hatime Arzu Yaşar, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut, Yüksel Ürün
{"title":"Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.","authors":"Beliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, Eda Eylemer Mocan, Elif Berna Köksoy, Hatime Arzu Yaşar, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut, Yüksel Ürün","doi":"10.1080/1750743X.2024.2370231","DOIUrl":"10.1080/1750743X.2024.2370231","url":null,"abstract":"<p><p><b>Background:</b> Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear.<b>Objective:</b> Assessing the association of pre- and post-ICI treatment sodium levels with survival.<b>Methods:</b> We retrospectively analyzed patients receiving ICI in January 2012-December 2023, collecting serum sodium levels at treatment initiation and 4 weeks post-ICI, with overall survival (OS) as the primary outcome.<b>Results:</b> Low sodium was observed in 125 and 119 patients pre-and post-treatment respectively. Pre-ICI and post-ICI low sodium correlated with decreased OS [10.6 vs. 22.9 months (<i>p</i> = 0.001) and 11.6 vs. 27.2 months (<i>p</i> = 0.009)]. Multivariate analysis identified pre-ICI low sodium [HR: 1.685; 95% CI: 1.050-2.705; <i>p</i> = 0.031] as an independent risk factor for worse OS.<b>Conclusion:</b> Low baseline serum sodium was an independent risk factor for poor OS in patients treated with ICIs.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"821-828"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. 免疫肿瘤学治疗晚期黑色素瘤的真实结果：OPTIMIzE注册研究的最终结果。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2023-11-08 DOI: 10.2217/imt-2022-0292
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Corey Ritchings, Trong Kim Le, Boas Park, Scott Ramsey
{"title":"Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.","authors":"John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Corey Ritchings, Trong Kim Le, Boas Park, Scott Ramsey","doi":"10.2217/imt-2022-0292","DOIUrl":"10.2217/imt-2022-0292","url":null,"abstract":"<p><p><b>Aim:</b> The OPTIMIzE registry study evaluated real-world outcomes in patients with advanced melanoma receiving immuno-oncology therapies. <b>Materials and methods:</b> Data were collected for patients treated with anti-programmed death 1 (PD-1) monotherapy (nivolumab or pembrolizumab; n = 147) or nivolumab plus ipilimumab (n = 81) from 2015-2017 and followed for ≥3 years. <b>Results:</b> Nivolumab plus ipilimumab versus anti-PD-1 monotherapy was associated with a nonsignificantly lower risk of death (adjusted HR: 0.83; 95% CI: 0.54-1.28; p = 0.41), higher disease control rate (72 vs 56%; p = 0.04), and stable quality of life, but more grade 3-4 treatment-related adverse events (54 vs 26%; p < 0.0001). <b>Conclusion:</b> These results support the use of immuno-oncology therapy in advanced melanoma.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"29-42"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71481073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab in an HIV-infected patient with glioblastoma. Pembrolizumab治疗一名感染艾滋病毒的胶质母细胞瘤患者。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2362566
Carlen A Yuen, Silin Bao, Melike Pekmezci, Fan Mo, Xiao-Tang Kong
{"title":"Pembrolizumab in an HIV-infected patient with glioblastoma.","authors":"Carlen A Yuen, Silin Bao, Melike Pekmezci, Fan Mo, Xiao-Tang Kong","doi":"10.1080/1750743X.2024.2362566","DOIUrl":"10.1080/1750743X.2024.2362566","url":null,"abstract":"<p><p>Persons living with human immunodeficiency virus (PLWH) carry increased risk for developing malignancies, including glioblastoma. Despite extensive investigations, both human immunodeficiency virus (HIV) and glioblastoma are incurable. Treatment for a patient with combined glioblastoma and HIV remains an unexplored need. Preliminary evidence suggests that immunotherapy may be effective for the simultaneous treatment of both HIV and cancer by reversing HIV latency and T cell exhaustion. We present a case of glioblastoma in a PLWH who was treated with pembrolizumab. Treatment was well tolerated and safe with a mixed response. Our patient did not develop any opportunistic infections, immune-related adverse events, or worsening of his immunodeficiency. To our knowledge, this is the first reported case of a PLWH and glioblastoma treated with immunotherapy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"803-811"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信